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Brief report 
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Abstract 
Pleurisy of initially unknown origin was found in a patient who was treated with bromocriptine for Parkinson’s disease 
for 6 years. At presentation, bilateral pleural thickening existed that caused severe restriction of pulmonary function. There 
were an elevated erythrocyte sedimentation rate, polyclonal hypergammaglobulinaemia, increased levels of acute phase 
proteins and anaemia. After withdrawal of the bromocriptine the patient’s complaints as well as the laboratory parameters 
markedly improved. Further loss of pulmonary function did not occur. However, the pleural thickening did not resolve, not 
even upon subsequent corticosteroid treatment, probably due to fibrosis. Together, these findings strongly suggest a 
causative role of bromocriptine. The results of the laboratory studies suggested an immunopathogenetic mechanism, but in 
vitro lymphocyte-proliferation studies and skin patch tests with bromocriptine were negative. Bromocriptine should be 
considered as a cause of pleurisy. The drug must be stopped immediately upon the occurrence of pleural thickening in order 
to prevent impairment of pulmonary function. In addition, periodic laboratory and X-ray studies in patients on long-term 
bromocriptine treatment should be considered. 
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1. Introduction 
Pleurisy can be a manifestation of a large number 
of different clinical entities, such as infectious, ma- 
lignant or autoimmune diseases or toxic conditions. 
Here we report on a case of bilateral pleurisy associ- 
ated with the use of bromocriptine for Parkinson’s 
disease. 
* Corresponding author. 
2. Case report 
A 66-year-old man suffering from mild Parlcin- 
son’s disease for 15 years was admitted in Septem- 
ber 1993 because of progressive thoracic discomfort, 
dry cough and dyspnoea that had existed for 7 
months. An involuntary weight loss of 5 kg had 
occurred in this period. Neither the patient nor his 
family had a history of pulmonary, cardiac or other 
systemic diseases. He had been a heavy smoker but 
stopped smoking 20 years ago. He denied occupa- 
tional exposure to asbestos. His medication consisted 
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Fig. 1. Laboratory parameters (ESR, the concentration of C-reac- 
tive protein and haemoglobin) during bromocriptine treatment (15 
mg daily), after withdrawal of this drug and during prednisone 
treatment (20 mg daily). 
of bromocriptine (lo- 15 mg daily since 1987), lev- 
odopa-carbidopa and baclofen. 
Physical examination disclosed no abnormalities 
other than bilaterally slightly dimmed percussion of 
the latero-basal thorax with fine inspiratory crackles, 
but was otherwise unremarkable. The temperature 
was 37.3”C. Laboratory studies showed a nor- 
mochromic, normocytic anaemia, an elevated ery- 
throcyte sedimentation rate and CFW concentration 
(Fig. 1) as well as increased levels of the acute-phase 
proteins haptoglobin (3.4 g/l, normal range 0.4-2.5 
g/l) and ferritin (473 pg/l, normal range 30-240 
pg/l). Analysis of the serum protein spectrum re- 
vealed increased levels of qglobulins and a poly- 
clonal hypergammaglobulinaemia. IgG, IgA and IgM 
concentrations were 25.4 g/l (normal range 8.0- 18.0 
g/l), 4.84 g/l (normal range 0.9-4.5 g/l) and 1.26 
g/l (normal range 0.6-2.8 g/l), respectively. The 
white-blood-cell count was just below the upper 
normal limit (9.8 X log/l, 72% neutrophils, 20% 
lymphocytes, 8% monocytes). Autoantibodies (ANA, 
anti-ds-DNA, rheumatoid factors) were not de- 
tectable. Arterial blood gas analysis was normal. 
The chest X-ray showed bilateral laterobasal pleu- 
ral thickening with partial compression atelectasis of 
the left lung (Fig. 2~). A previous chest X-ray made 
in 1984 because of transient coughing was normal 
(Fig. 2a). The chest X-ray made in 199 1, also be- 
cause of transient coughing, showed only blunting of 
the costo-phrenic sinuses, a pleural streak in the 
midfield of the left lung and small pleural adhesions 
above the right diaphragm and beside the apex of the 
Fig. 2. Chest X-ray films 3 years before (A), during 4 (B) and 6 
(C) years of treatment with bromocriptine for Parkinson’s disease. 
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heart (Fig. 2b). Further investigations or follow-up 
chest X-ray studies were not carried out at that time. 
The findings on the present X-ray were confirmed by 
CT-scan. Neither parenchymal abnormalities of the 
lungs nor enlarged thoracic or abdominal lymphomas 
nor retroperitoneal fibrosis were present. Pleural fluid 
could not be obtained by puncture and was not 
demonstrated by subsequent echography. Pulmonary 
function tests showed a restrictive disorder (TLC 
66%, FRC 61% of the predicted value) without 
airway obstruction. 
Further aetiological studies including bron- 
choscopy with transbronchial biopsy, cultures of the 
sputum and PPD-skin test were all unremarkable. In 
the meantime the complaints of the patient worsened 
as did the results of the laboratory studies: the ESR 
and CRP concentration rose further, and the 
haemoglobin concentration further decreased (Fig. 
1). Because of several reports that suggested a rela- 
tion between pleuropulmonary disease and the use of 
bromocriptine [l-9] we conducted in vitro and in 
vivo immunological studies to confirm bromocrip- 
tine hypersensitivity as the aetiological factor in our 
patient. Skin patch tests and in vitro lymphocyte-pro- 
liferation studies using the patient’s peripheral blood 
mononuclear cells were carried out with different 
concentrations of bromocriptine mesylate (final con- 
centrations ranging from 0.2 to 125 rig/ml; thera- 
peutic plasma concentration in Parkinson’s disease 
patients ranging from 0.4 to 1.3 rig/ml). Both tests 
were negative with positive responses to control 
antigens. 
Notwithstanding these results, we discontinued 
the bromocriptine medication by tapering it off in 2 
weeks time. Four weeks after the bromocriptine had 
been completely stopped, the patient reported a sub- 
stantial improvement of the thoracic discomfort, dis- 
appearance of the dry cough, reduction of dyspnoea 
and a weight gain of 3 kg. The laboratory abnormali- 
ties also improved (Fig. 1). The IgG concentration in 
the serum decreased slightly to 21.8 g/l. Although 
the complaints and laboratory abnormalities further 
declined in the next months, they remained at a 
lower level and the X-rays of the chest showed no 
improvement. Therefore, prednisone 20 mg daily 
was instituted. Within 6 weeks, the remaining tho- 
racic discomfort and dyspnoea completely resolved. 
Laboratory parameters normalized (Fig. 1), including 
the hypergammaglobulinaemia (IgG and IgA concen- 
trations declined to 14.8 and 2.84 g/l, respectively). 
However, neither the chest X-ray and the CT-scan 
nor the pulmonary function tests (TLC 68%, FRC 
61% of the predicted value) showed any improve- 
ment. The corticosteroid therapy is currently being 
tapered off without any sign of reactivation of the 
inflammatory process. 
3. Discussion 
Long-term bromocriptine therapy has been used 
world-wide over the past two decades in large num- 
bers of patients. Indications for bromocriptine in- 
clude Parkinson’s disease, prolactinoma and 
acromegaly. More recently, it has been used in in- 
flammatory diseases such as arthritis psoriatica [lo] 
and iridocyclitis [ 111, and in immunosuppressive reg- 
imens after transplantation [ 12,131, because 
bromocriptine interferes with the intracellular sig- 
nalling of several cytokines [14]. However, to our 
knowledge, to date, only 30 cases of bromocriptine- 
induced pleurisy have been described in the English 
language medical literature [l-9,15]. This suggests 
that pleurisy is a rare complication of the use of 
bromocriptine. Alternatively, it is also possible that 
bromocriptine is often not recognized as a causative 
agent in patients with pleurisy. Upon introduction of 
bromocriptine, initial studies on the safety of this 
drug described pleurisy in 6 out of 123 patients 
treated [l]. The daily doses in that study were sub- 
stantially higher than those used nowadays and 
ranged from 30 to 100 mg. This might explain the 
relatively high frequency of pleurisy in those pa- 
tients. However, more recently pleurisy was also 
found in 2 out of 62 patients with Parkinson’s dis- 
ease taking less than 30 mg daily in a prospective 
5-year follow-up study on the use of bromocriptine 
[15]. Similarly to our patient, all patients described 
until now were men over 50 years of age treated for 
Parkinson’s disease. In all cases complaints and ab- 
normalities in laboratory and X-ray investigations 
developed after l-5 years of treatment with 
bromocriptine in daily doses of at least 15 mg. 
Retrospectively, it might be argued that the mild 
abnormalities present on the chest X-ray film of our 
patient in 1991 were also caused by bromocriptine. 
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In addition, pleural effusion with non-specific lym- 
pbocytic pleocytosis was frequently described [l- 
9,151. Our patient, however, bad no detectable 
amounts of fluid in the pleural cavity. Presumably, 
be bad a more advanced stage of pleurisy with 
organisation and subsequent fibrosis of the pleural 
exudate that bad been present earlier in the disease. 
The poor response to withdrawal of bromocriptine 
and the subsequent institution of prednisone therapy, 
as indicated by the X-ray studies and pulmonary 
function tests, support this hypothesis. 
The striking relation between the withdrawal of 
bromocriptine in this patient and those described 
previously [l-9] and the improvement of the clinical 
and laboratory findings provides strong circumstan- 
tial evidence for a causative role of bromocriptine in 
the development of pleurisy. However, the pathogen- 
esis is unclear. Idiosyncrasy cannot be ruled out, but 
the increased levels of acute-phase proteins and the 
polyclonal bypergammaglobulinaemia suggest that 
immunological mechanisms might be operating. To 
our knowledge we are the first to address this possi- 
bility by immunological studies. Definite proof is 
lacking as the skin tests and lymphocyte stimulation 
tests were negative. This might be due to the fact 
that bromocriptine does not provoke an immune 
reaction directly, but merely acts like a bapten, which 
together with pleural determinants forms the anti- 
genie stimulus for immunologically mediated injury. 
In addition to pleural fibrosis, bromocriptine has also 
been implicated in the development of retroperi- 
toneal fibrosis with similar abnormalities in labora- 
tory studies, suggesting a common pathogenetic 
mechanism [4,15- 181. Fibrotic inflammatory disor- 
ders of the pleura and retroperitoneal fibrosis have 
also been descibed during the long-term use of the 
alkylated ergot derivative, methysergide, which has a 
molecular structure related to that of bromocriptine 
[19-211. Direct proof that metbysergide plays a 
causative role in these disorders is also lacking, but 
the abnormalities remitted after withdrawal of the 
drug, as we described for bromocriptine. 
In conclusion, bromocriptine should be consid- 
ered as a causative agent when pleurisy occurs, even 
if the daily dose is low. In such cases the drug 
should be stopped and corticosteroid treatment is 
possibly beneficial in order to prevent formation of 
irreversible pleural thickening with impairment of 
pulmonary function. In addition, periodic laboratory 
and X-ray studies in patients on long-term 
bromocriptine therapy are recommended. 
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